Application of ridecevir in preparation of medicine for preventing and treating reperfusion injury

A technology for reperfusion injury and drugs, applied in the field of biomedicine, to achieve the effect of improving application potential and market prospects

Active Publication Date: 2022-03-08
北京箭牧科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to the literature information, there is no domestic and foreign lite

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ridecevir in preparation of medicine for preventing and treating reperfusion injury
  • Application of ridecevir in preparation of medicine for preventing and treating reperfusion injury
  • Application of ridecevir in preparation of medicine for preventing and treating reperfusion injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1 Cardiac ischemia-reperfusion mouse model construction

[0028] 1. Experimental materials

[0029] 1. Experimental animals: C57BL / 6 mice, 8-week-old male, weighing 20-24 g, SPF grade, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.

[0030] 2. Experimental reagents: Masson trichrome staining kit (purchased from Wuhan Sevier Biotechnology Co., Ltd.).

[0031] 2. Experimental steps

[0032] The cardiac ischemia-reperfusion model was established by ligating the left anterior descending coronary artery in mice. Open the thorax of the mouse to squeeze out the heart, ligate the left anterior descending coronary artery at about 2 mm below the left atrial appendage, tie a slipknot, observe the heart at the apex of the heart turns white, and the electrocardiogram shows ST-segment elevation changes can confirm the occurrence of ischemia, close the chest After 45 minutes, the slipknot was released, and the ST segment of the electrocardi...

Embodiment 2

[0041] Example 2 The protective effect of remdesivir on cardiac ischemia-reperfusion

[0042] 1. Experimental materials

[0043] 1. Remdesivir: purchased from Shanghai Taosu Biochemical Technology Co., Ltd., protected from light, sealed, and dried at 4°C. The drug was first dissolved in 100% dimethylsulfoxide (DMSO, purchased from sigma), and then diluted to 10% with corn oil (purchased from MCE).

[0044] All the other are with embodiment 1.

[0045] 2. Experimental group

[0046] Blank control group (solvent group), Remdesivir group (20mg / kg, po), Remdesivir group (30mg / kg, po), Remdesivir group (40mg / kg, po), Remdesivir Wei group (50mg / kg, po), remdesivir group (60mg / kg, po).

[0047] 3. Experimental steps

[0048] Select C57BL / 6 (male, about 8 weeks old, 20-24g) mice, randomly divide them into groups, 10 mice (n=10) in each group, and administer them after weighing, once a day, and after 3 days of continuous oral administration Establishment of cardiac ischemia-reper...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of Redesivir (Redesivir) in a medicine for preventing and treating reperfusion injury, especially heart reperfusion injury. The invention verifies the great potential of the ridecavir as the medicine for preventing and treating the heart ischemia reperfusion injury, discloses a good protection curative effect of the ridecavir on the heart ischemia reperfusion injury for the first time, provides an effective novel potential alternative medicine for clinical prevention and treatment of the reperfusion injury, expands the adaptation of the ridecavir, and has a good application prospect in prevention and treatment of the heart ischemia reperfusion injury. The application potential and the market prospect of the ridecevir are greatly improved.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to the application of remdesivir in the preparation of drugs for the prevention and treatment of reperfusion injury, especially cardiac ischemia-reperfusion injury. Background technique [0002] Remdesivir (RDV, GS-5734) is a nucleoside analog antiviral drug developed by Gilead Sciences (GILD) that works by inhibiting viral nucleic acid synthesis. [0003] In the patent WO2009132123A1, the general formula of the compound structure of Remdesivir was proposed for the first time, which is used for the treatment of hepatitis C virus infection, dengue fever and other flaviviridae virus infection diseases. Patent WO2012012776A1 proposes the effect of Remdesivir in treating diseases infected by Paramyxoviridae viruses. In subsequent patents, it is also proposed that RDV can be used as an anti-filovirus, anti-arenavirus and anti-coronavirus drug. According to the literature information,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/685A61P9/10
CPCA61K31/685A61P9/10Y02A50/30
Inventor 崔庆华徐明王佳星
Owner 北京箭牧科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products